𝗖𝗮𝗻 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗺𝗮𝗸𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗺𝗼𝗿𝗲 𝗮𝗳𝗳𝗼𝗿𝗱𝗮𝗯𝗹𝗲?
Governments like South Korea are introducing pricing caps on 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀, 𝗶𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗯𝗼𝗼𝘀𝘁𝗶𝗻𝗴 𝗮𝗱𝗼𝗽𝘁𝗶𝗼𝗻 across APAC.
𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://www.kenresearch.com/industry-reports/asia-pacific-biopharmaceuticals-market?utm_source=Mastadon&utm_medium=Social&utm_campaign=Aniket

#Biosimilars #HealthcareAccess #PharmaPolicy #APAC

Alvotech Reports Positive PK Results for AVT80

Alvotech has announced top-line results from a pivotal pharmacokinetic study of AVT80, a proposed biosimilar to Entyvio (vedolizumab). The randomized, double-blind, 3-arm study assessed PK similarity, safety, and immunogenicity in healthy adults after a single 108 mg/0.68 mL subcutaneous injection. The data supports the development of the candidate for patients worldwide.

#Alvotech #biosimilars #biotech #lifescience

Alvotech Secures Global Settlement for Aflibercept Biosimilar

Alvotech reached a settlement to market its biosimilar globally. Entry starts Jan 1, 2026, in the UK and Canada. The EEA and other regions follow May 1, 2026. Japan allows full indications by Nov 1, 2026. Combined with a US Q4 2026 license, the company secures worldwide rights to supply partners, subject to regulatory approval.

#biotech #biosimilars #lifescience #Alvotech

Nearly 70% of cancer patients face financial crises within one year after leaving hospital, highlighting urgent need for support. Hospital K suggests using biosimilars to reduce costs and improve treatment access.

#cancercare #financialcrisis #healthpolicy #access2medicine #unreadyposts #VietnamHealth #SustainableHealthcare #biosimilars #patientrights #VietnamNet

#ungthư #sứckhỏe #chínhsách y tế #khủnghoảngtàichính #dượcphẩmsinhhọc #tiếpcậnđiềutrị #bệnhviệnK #côngbằngy tế #sốngkhỏemạnh #vietn